# Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

> **NCT07050524** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 80 (estimated)

## Conditions studied

- Gastric Cancer Stage III

## Interventions

- **DIETARY_SUPPLEMENT:** Omega-3 Supplementation
- **DRUG:** Neoadjuvant Immunotherapy

## Key facts

- **NCT ID:** NCT07050524
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050524, "Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07050524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*